
StageZero Life Sciences Investor Relations Material
Latest events

Q1 2024
StageZero Life Sciences

Q3 2024
15 Dec, 2024

Q2 2024
1 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from StageZero Life Sciences Ltd
Access all reports
StageZero Life Sciences Ltd. specializes in providing molecular diagnostic solutions, leveraging a telehealth program that employs advanced diagnostics for the early detection of cancer and chronic diseases. The company is known for developing blood-based biomarker tests, particularly for identifying colorectal cancer. A key innovation from StageZero is its Sentinel Principle technology, which is instrumental in early disease diagnosis, staging, response identification, and treatment monitoring. Additionally, StageZero offers Aristotle, an mRNA-based test capable of detecting multiple cancers from a single blood sample. StageZero Life Sciences is headquartered in Richmond Hill, Ontario, and its shares are listed on the Toronto Stock Exchange.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SZLS
Country
🇨🇦 Canada